Navigation Links
Method reveals new view of human nerve cells, opening door to potential drug targets
Date:3/11/2011

in neurons," says Bartfai. "With other methods you miss receptors present in only a few copies. But that does not mean that they are not important."

Revealing Neurons' Complexity

Using their new method Bartfai and Eberwine identified more than 400 receptors active in warm sensitive neurons. About one-third of the receptors are so-called "orphan" receptors, meaning the chemicals they bind to are unknown. The rest were receptors whose ligands (substances they bind to) are knownamong them, the authors found a few surprises.

For example, Bartfai and Eberwine discovered that the receptor responsible for binding insulin is active on warm sensitive neuronssomething no one had previously suspected.

The insulin receptor is known to be involved in regulating a person's metabolism. Follow-up studies by Bartfai's group have now shown that insulin binds to receptors on warm sensitive neurons to decrease their activity, causing an increase in body temperature, or hyperthermia. Thus, insulin is a key regulator for both body metabolism and temperature.

"This study highlights the complexity of these cells by showing us the large number of different RNAs that are present," said Eberwine.

Game-Changing Research

In addition to providing important insights into the complexity of nerve cells, the study has implications for identifying potential drug targets for diseases that currently have few or no treatments.

"We would like to repeat similar studies for key neurons involved in Parkinson's disease and schizophrenia," explained Bartfai. "If we again discover 400 receptors, we could then ask which ones are reasonably selectively expressed in these neurons." Any receptor active primarily in one class of neurons involved in a particular disease process represents a possible target for developing drugs to affect the course of that disease.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Commercial aquatic plants offer cost-effective method for treating wastewater
2. UC Riverside biochemists devise method for bypassing aluminum toxicity effects in plants
3. New lab manual focuses on essential methods for purifying and characterizing proteins
4. Deep biosphere research points to new methods for recovering petroleum
5. Fingerprinting method tracks mercury emissions from coal
6. Iowa State researcher develops new treatment method for canine eye diseases
7. New method provides panoramic view of protein-RNA interactions in living cells
8. Cold Spring Harbor Protocols features organ and cell culture methods
9. Engineer to present leak-proof method for carbon dioxide storage at international conference
10. Pitt researchers use fluorescence to develop method for detecting mercury in fish
11. New holographic method could be used for lab-on-a-chip technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... have created the first three-dimensional living tissue model, complete ... therapeutics to combat brain tumors. The 3-D model gives ... tissue cultures. The researchers created a glioma, or ... surrounds it. In a series of experiments, the team ...
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... Resolving the world,s major challenges whether climate change, ... scarcity requires a sweeping shift in our approach ... leading scientists told European policy makers today during ... and Societal Challenges for our Unstable Earth" (RESCUE). ...
Cached Biology News:Researchers make living model of brain tumor 2Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 14 Bio-Optronics, Inc., a leader in healthcare workflow ... software solution that can simultaneously handle the most intricate scheduling ... staff schedules. , , Physician ... , Bio-Optronics President & CEO, ...
... , HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine ... entered into an agreement to exclusively license seven ... company. These proprietary antigens specifically target breast, ovarian ... antigens with its DepoVax(TM) delivery platform to develop ...
... , , TAMPA, Fla., July ... on the research and development of cancer immunotherapies, announces that the ... its dendritic cell therapy. , , ... I/II clinical trial testing the safety and efficacy of its immunotherapy ...
Cached Biology Technology:NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3